Cargando…
The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib
Tyrosine kinase inhibitors (TKIs) like dasatinib and nilotinib are indicated as second-line treatment for chronic myeloid leukemia resistant or intolerant to the current first-line TKI imatinib. These are agents are well tolerated, but potent and as such should be monitored for potentially serious s...
| Autores principales: | , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2009
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2785832/ https://www.ncbi.nlm.nih.gov/pubmed/19909541 http://dx.doi.org/10.1186/1756-8722-2-46 |